US 12,404,344

Application 17/893,515 · Granted Sep 2, 2025

Low-viscosity, high concentration evolocumab formulations and methods of making the same

Estimated expiration

April 1, 2039

12y 134d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Feb 22, 2018
+ 20 years
Feb 22, 2038
PTA +403d
Apr 1, 2039
No TD
—
Final
Apr 1, 2039

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
August 23, 2022
Earliest effective filing
February 22, 2018
Issue date
September 2, 2025
PTA
+403 days
Base expiry (before PTA)
February 22, 2038

February 22, 2018 + 20 years = February 22, 2038 + 403 PTA days = April 1, 2039

  • Divisional of application 15/902,775, filed Feb 22, 2018, issued as US 11,464,857
  • PRO62/462,266 — Provisional — not used for base term
  • PRO62/462,266 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/893,515 · US 12,404,344

PatentReply compiles the prosecution history behind US 12,404,344: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12404344

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.